GEN

Ferring Gains Option to FKD’s Phase III Bladder Cancer Gene Therapy Candidate

Ferring Pharmaceuticals said today it has acquired the option to secure global commercialization rights to FKD Therapies’ Phase III bladder cancer gene therapy candidate nadofaragene firadenovec/Syn3, ...
GEN

FKD Therapies Acquires Exclusive License to Merck & Co.’s Gene Therapy Portfolio

Pipeline is headed by Phase II-ready recombinant adenoviral interferon alfa 2b for treating superficial bladder cancer. Merck & Co. has taken an equity stake in newly established Finnish gene ...
The Independent

UK’s youngest terror offender walks free from court after recruiting for neo-Nazi group

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails The UK’s youngest ...